





# CAR-T therapies are manufactured for each individual patient

For decades, researchers have pursued various ways to utilize the human immune system to fight cancer. Through these researchers' innovation and perseverance, autologous CAR-T therapies were discovered.

In contrast to typical small molecule or biologic products, autologous CAR-T therapies are specifically manufactured for each individual patient and require a paradigm shift in the approach to manufacturing, logistics and administration.

Through a collaboration with the University of Pennsylvania (Penn), Novartis made an early commitment to the emerging field of CAR-T therapies. Its facility in Morris Plains, New Jersey, was the first manufacturing site approved by the FDA for immunocellular therapy production in the US, and has manufactured CAR-T cells for hundreds of patients in global clinical trials.

